Working Groups

  • Industry Collaboration 
  • Cost-Effectiveness
  • Psychosocial Studies
  • Ethics

The Industry Collaboration Group aims to bring together industry partners and cure researchers to facilitate and encourage interactions and collaborations. The Industry Collaboration Group is co-chaired by two academic representatives (David Margolis, UNC and Sarah Palmer, The University of Sydney) and two industry representatives (Guenter Kraus, Janssen and Jim Demarest, ViiV Healthcare) and the aim of the group is to foster the involvement of industry to develop a safe, accessible and scalable cure for HIV.

 

Common Material Transfer Agreement (cMTA)

A major achievement to accelerate HIV cure research and lighten the red-tape burden for preclinical studies, was the development of a common Material Transfer Agreement (cMTA) by the IAS Industry Collaboration Group for combinational use of marketed compound in antiretroviral therapy.  The finalisation of the agreement, approved by ViiV Healthcare, Gilead, Bristol-Myers Squibb, Johnson & Johnson, and Merck, was announced in January 2016.

To read more about the role of the cMTA and its anticipated impact in the field, please read the IAS blog article, co-authored by Members of the Towards an HIV Cure ICG.

 

Working Group Members:

 

  • Alan Landay, Rush University Medical Center, USA
  • Anna-Laura Ross, IAS/ANRS, France
  • Brian Johns, GlaxoSmithKline, USA
  • Bryan Cobb, Roche, USA
  • Carey Hwang, Bristol-Myers Squibb, USA
  • Carl Dieffenbach, National Institute of Allergy and Infectious Diseases/National Institutes of Health (NIAID/NIH), USA
  • Christine Rouzioux, University Paris Descartes/Hôpital Necker, France
  • Christos J Petropoulos, Monogram Biosciences, USA
  • Dara Wright, eBioscience, Inc., USA
  • Daria Hazuda, Merck, USA
  • David Margolis, University of North Carolina at Chapel Hill (UNC), USA
  • Deborah Persaud, John Hopkins University School of Medicine, USA
  • Françoise Barré-Sinoussi, Institut Pasteur, France
  • Giuseppe Pantaleo, University of Lausanne, Switzerland
  • Guenter Kraus, Janssen, USA
  • Guido Poli, San Raffaele University and Scientific Institute, Italy
  • Guido Silvestri, Emory University, USA
  • Hans-Peter Kiem, Fred Hutchinson Cancer Research Center, USA
  • Harriet Robinson, GeoVax Inc, USA
  • Jan van Lunzen, ViiV Healthcare, United Kingdom
  • Javier Martinez-Picado, irsiCaixa Foundation, Spain
  • Jean-François Delfraissy, Agence Nationale de Recherche sur le SIDA et les hépatites virales (ANRS), France
  • Jeff Sheehy, California Institute for Regenerative Medicine, USA
  • Jeffrey Lifson, National Cancer Institute at Frederick, USA
  • Jim Demarest, ViiV Healthcare, USA
  • Jintanat Ananworanich, US Military HIV Research Program, USA
  • John Mellors, University of Pittsburgh, USA
  • Lars Østergaard, Aarhus University Hospital, Denmark
  • Lynda Dee, AIDS Action Baltimore, CARE CAB, USA
  • Maja Sommerfelt, Bionor Pharma ASA, Norway
  • Michael Busch, Blood Systems Research Institute, USA
  • Michael Lederman, Case Western Reserve University, USA
  • Nikos Dedes, International Treatment Preparedness Coalition (ITPC), Global
  • Rama Amara, Emory University, USA
  • Robert Reinhard, Public/Global Health Consultant, Canada
  • Romas Geleziunas, Gilead Sciences Inc., USA
  • Rowena Johnston, The American Foundation for AIDS Research (amfAR), USA
  • Sarah Palmer, The University of Sydney, Australia
  • Sharon Lewin, Doherty Institute, The University of Melbourne, Australia
  • Stephen Mason, Bristol-Myers Squibb, USA
  • Steven Deeks, University of California, San Francisco (UCSF), USA
  • Therese Croughs, Institut National de la Santé et de la Recherche Médicale (INSERM), France
  • Tomas Cihlar, Gilead Sciences Inc., USA
  • Tri Do, Roche, USA
  • Veronica Miller, Berkeley/Forum for HIV Collaborative Research, USA
  • Yves Levy, Agence Nationale de Recherche sur le SIDA et les hépatites virales (ANRS), France

The Working Group on Public Health Impact and Cost-Effectiveness was established to respond to the need for a more in-depth consideration of cost-effectiveness in the IAS Global Scientific Strategy on HIV Cure. In 2015, the Working Group authored a paper on the role of mathematical modelling and cost-effectiveness analysis in the HIV cure research agenda, published in Journal of Virus Eradication.  The Working Group on Public Health Impact and Cost-Effectiveness also joined forces with the Psychosocial Studies Group to co-author a paper on integrating social science with biomedical research for multi-disciplinary HIV cure research, published in Trends in Microbiology.

Working Group Members:

  • Adaora Adimora, University of North Carolina at Chapel Hill, USA
  • Cristina PossasInstituto de Pesquisa Clínica Evandro Chagas-Fundação Oswaldo Cruz (IPEC-FIOCRUZ), Brazil
  • Giulio Maria CorbelliAnlaids, Italy
  • Karl-Lorenz DehneUNAIDS, Switzerland
  • Kenneth FreedbergHarvard School of Public Health, USA
  • Michele Di MascioNational Institute of Allergy and Infectious Diseases/National Institutes of Health (NIAID/NIH), USA
  • Rochelle WalenskyHarvard Medical School, USA
  • Steve DeeksUniversity of California, San Francisco (UCSF), USA
  • Yazdan YazdanpanahAssistance Publique-Hôpitaux de Paris (AP-HP), France

 

A multinational academic and community-based research team is developing a multi-country project to assess the willingness of patients’ to participate in HIV cure-related strategies and the potential impact of an HIV cure from a social and behavioral sciences perspective. In 2015, the Psychosocial Studies Group joined forces with the Working Group on Public Health Impact and Cost-Effectiveness to co-author a paper on integrating social science with biomedical research for multi-disciplinary HIV cure research, published in Trends in Microbiology.

Working Group Members:

  • Bruno SpireInstitut National de la Santé et de la Recherche Médicale (INSERM), France
  • Claris OjwangMoi University School of Medicine, Kenya
  • Cynthia Grossman, National Institutes of Health/National Institutes of Mental Health, USA
  • David EvansProject Inform, USA
  • Dianne RauschNational Institutes of Health/National Institutes of Mental Health, USA
  • Fred VerdultVolle-Maan, The Netherlands
  • Joseph Tucker, UNC Project – China, China
  • Judith AuerbachScience & Policy Consultant, USA
  • Julie Fox, King’s College London, United Kingdom
  • Marian PittsUniversity New South Wales, Australia
  • Marie SuzanInstitut National de la Santé et de la Recherche Médicale (INSERM), France
  • Michael ArnoldLegacy Project, USA
  • Nelson Vergel, Consultant, USA
  • Peter NewmanUniversity of Toronto, Canada
  • Veronica NosedaSidaction, France

 

The Working Group on Ethics completed their mandate upon publishing an article ‘Ethical Consideration in HIV Cure Research’ in a special edition on HIV Cure in Current Opinion in HIV and AIDS.

Ethics is integral to the questions of HIV cure research and should be incorporated across the Towards an HIV Cure initiative. Therefore, the Working Group on Ethics is no longer a stand-alone working group, but has been integrated into the other Working Groups to reinforce the ethical component.